Law360, New York (April 09, 2012, 1:35 PM ET) -- On March 26, 2012, U.S. medical device maker Biomet Inc. agreed with the U.S. Department of Justice and U.S. Securities and Exchange Commission to settle charges related to alleged bribes paid to obtain business in Argentina, Brazil and China. This is the third — though almost certainly not the last — Foreign Corrupt Practices Act settlement with medical device manufacturers.
In the wake of recent setbacks in the Shot Show and Lindsey cases, the settlement serves as a reminder that the U.S. government is still aggressively...
Continuing The Trend: Biomet's FCPA Settlement
To view the full article, take a free trial now.
